Full Press Release Details
• Pluri is translating more than two decades of cell-technology, manufacturing and clinical experience into a focused commercial strategy
• Regenerative medicine and the U.S. market are central to this next phase, supported by ZEO, CellaV and PluriCDMO
• Clinical progress, strategic partnerships and greater financial alignment provide multiple avenues to unlock value across Pluri’s asset base
HAIFA, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri” or the “Company”) today issued the following letter from Yaky Yanay, President and Chief Executive Officer, following the Company's October 29, 2026 investor update and the November 12, 2026 publication of its first-quarter fiscal 2027 results.
Dear Shareholders,
Following the release of our first-quarter fiscal 2027 results and our recent investor update, I would like to share our perspective on Pluri's progress and the opportunities ahead.
During our October 29 investor update, Pluri's Chairman and major shareholder, Alejandro Weinstein, and I highlighted two significant developments: our strategic agreement with ZEO ScientifiX, designed to accelerate our commercial expansion into the U.S. regenerative medicine market, and the agreement for an entity beneficially owned by Alejandro to acquire Pluri's European Investment Bank loan, representing a strong vote of confidence and an important step toward greater financial flexibility.
These developments support the next phase of Pluri's evolution. Over more than two decades, we have built a strong foundation of proprietary cell technology, advanced manufacturing capabilities, extensive clinical experience, and an intellectual property portfolio of more than 200 patents. We believe these assets represent significant potential value. Our focus now is on translating this foundation into commercial opportunities, with regenerative medicine, longevity, and the U.S. market at the center of our strategy. Our objective is clear: turning our technology, knowledge, and experience into products, partnerships, and sustainable revenue.
Regenerative Medicine and the U.S. Market
We believe regenerative medicine offers Pluri a significant opportunity to apply its experience to products with real medical and commercial relevance. The U.S. is central to this strategy, and Florida is an important starting point. Our objective is to connect credible science and reliable manufacturing with the physicians, patients and channels that can bring appropriate products to market under the applicable regulatory frameworks.
Our signed strategic agreement with ZEO ScientifiX, Inc. (“ZEO”) is designed to provide that connection. ZEO brings existing biologics operations in Florida, products already in market, physician relationships, professional education and sales infrastructure. Pluri brings its cell platform, clinical-development data, intellectual property and manufacturing experience. Subject to closing and the terms of the transaction, Pluri expects to hold 50% of ZEO. The agreement has been signed, and the work of completing the transaction and developing the combined commercial platform remains ahead of us.
CellaV: Extending Our Cell Science into Regenerative Aesthetics
CellaV is another practical expression of this approach. We have developed placenta-derived and plant-derived active ingredients and professional systems for regenerative skin and hair care. We intend to expand their reach through physician-dispensed channels, clinics and distribution partners, including through the ZEO platform in the U.S. The products and scientific foundation exist; the next stage is to establish consistent market adoption and repeat demand.
Chairman's Vote of Confidence Paves the Way for Greater Financial Flexibility
In October, we announced that an entity beneficially owned by our Chairman, Alejandro Weinstein, entered into an agreement to acquire Pluri's loan from the European Investment Bank (the “EIB”). The loan transfer subsequently closed effective November 4, 2026, and we were released from our obligations to the EIB. We expect to enter into separate agreements with the acquiring entity regarding the settlement of the loan. We view this transaction as a strong expression of long-term confidence in Pluri and an important step toward creating greater alignment and flexibility as we execute our strategy. With our chairman also serving as a principal shareholder, we believe this structure further aligns the interests of our leadership and shareholders as we focus on commercial execution and long-term value creation.
PluriCDMO: Building a Recurring Commercial Business
PluriCDMO allows us to offer development and manufacturing services using infrastructure and experience built over many years. This includes cell-based programs supported by our manufacturing and quality capabilities. Our recently announced ISO 9001 and ISO 13485 Certifications also enable us to extend our offerings to current and new customers requiring those quality standards, in addition to our cGMP cell capabilities.
Unlocking Value from Our Therapeutic Pipeline
Our therapeutic programs continue to represent an important source of value and opportunity for Pluri. Charité in Berlin, recently announced the successful completion of the first step of the PROTO Phase I clinical trial and indicated that the second step is expected to commence in January 2027, subject to a favorable safety review. The study, evaluating PLX-PAD cells in a treatment for mild to moderate knee osteoarthritis, is being conducted as part of the EU-supported PROTO collaboration, which was awarded a €7.5 million non-dilutive grant under the Horizon Europe program.
We remain strong believers in the potential of our cells and in the value of the extensive clinical experience and data we have built over the years. As the healthcare and longevity landscape evolves, we are evaluating regulatory pathways and strategic opportunities that could enable us to advance selected assets in our pipeline, including through external funding and partnerships. Our approach will remain focused and disciplined, prioritizing opportunities where the regulatory pathway, capital requirements and potential value creation are well aligned.
Pluri today has more ways to create value from its technology and assets than at any previous point in its development. Our priorities are clear: establish a meaningful commercial presence in regenerative medicine, expand our U.S. market access, grow recurring revenue through PluriCDMO and CellaV, and selectively advance opportunities across our therapeutic and broader asset base.
We are relying on more than two decades of knowledge and data, manufacturing capabilities, clinical experience and intellectual property behind Pluri. Our focus now is on translating that foundation into commercial execution and long-term value. Thank you for your continued support and confidence in Pluri.
Sincerely,
Yaky Yanay President and Chief Executive Officer Pluri Inc.
About Pluri Inc.
Pluri Inc. (Nasdaq and TASE: PLUR) develops cell-based technologies and products using its proprietary 3D cell-expansion platform and manufacturing capabilities. The Company's activities include regenerative medicine, longevity, regenerative aesthetics and CDMO services, as well as portfolio companies and strategic partnerships. For more information, visit https://pluri-biotech.com/. View the investor update replay: https://www.youtube.com/watch?v=5ehOwxIUMcs
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. For example, Pluri is using forward-looking statements when it discusses its strategy and plans to translate its cell technology, manufacturing capabilities, clinical experience and intellectual property into commercial opportunities; its plans to establish a commercial presence in regenerative medicine, expand its access to the U.S. market and grow recurring revenue through PluriCDMO and CellaV; the anticipated benefits of, and Pluri’s ability to complete and implement the transactions contemplated by, its agreement with ZEO, including Pluri’s expected ownership of 50% of ZEO following closing; the potential expansion of CellaV’s products in the United States; the potential for the transfer of Pluri’s loan from the EIB to provide greater financial flexibility; Pluri’s expectation that it will enter into separate agreements with the acquiring entity regarding the settlement of the loan; and Pluri’s plans to evaluate regulatory pathways and other strategic opportunities to advance selected therapeutic programs and other assets. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the possibility that Pluri’s commercialization strategy is delayed, unsuccessful or does not result in anticipated revenues or other benefits; the possibility that the transactions contemplated by the agreement with ZEO are delayed or do not close; the possibility that the anticipated operational, commercial and strategic benefits of the ZEO transaction are not realized; Pluri’s and ZEO’s ability to obtain sufficient financing and successfully implement the contemplated operating and commercialization plans; the possibility that CellaV’s products do not achieve consistent market adoption or repeat demand; the possibility that PluriCDMO does not attract additional customers, programs or revenue; the inability of Pluri to reach definitive agreements regarding the settlement of the transferred loan, or to obtain terms that provide the anticipated financial flexibility; the availability of external funding and strategic partners for Pluri’s therapeutic programs; the timing and results of clinical trials and regulatory review; the Company's ability to successfully execute its commercialization and strategic initiatives; changes in economic, business, market or regulatory conditions; inability to retain or attract key employees; increased competition, loss of market share or pricing pressure; inability to timely develop and introduce new technologies, products and applications; and other risks and uncertainties that may affect the Company's business. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.